Halo Pharmaceutical, ExxPharma Therapeutics Collaborate
News Apr 21, 2016
ExxPharma Therapeutics LLC (“ExxPharma”) and Halo Pharmaceutical Inc. (“Halo”) have entered into a collaboration agreement to develop and manufacture drug products for customers of Halo and ExxPharma using ExxPharma’s innovative drug delivery systems and twin screw extrusion-based manufacturing technology. ExxPharma will be responsible for technical development while Halo will have overall responsibility of drug product manufacturing and quality control at Halo’s GMP-compliant manufacturing facility in Whippany, NJ.
Twin screw extrusion is a highly versatile and precisely-controlled continuous manufacturing process that utilizes small mass mixing to improve efficiency, maximize quality and reduce cost. The technology, while relatively new to the pharmaceutical industry, has been gaining wide acceptance especially with hot melt extrusion (HME) which ExxPharma and others have used effectively to improve the bioavailability of poorly soluble drug substances.
“Collaborating with Halo offers us the opportunity to serve our clients more efficiently using fully integrated, cost-effective complementary services that encompass formulation/process feasibility studies, Phase I to Phase III clinical development and commercial production,” said Isaac GhebreSellassie, Founder and President of ExxPharma, which is based in Morris Plains, NJ.
“Halo has an impressive track record of manufacturing clinical trial material and commercial drug products both for U.S. and European markets. This collaboration allows us to seamlessly transfer analytical and manufacturing technologies from a research and development environment at ExxPharma to a GMP compliant manufacturing facility.”
“We are excited about this collaboration with ExxPharma as it allows us to provide an alternative technology to our customers”, said Lee Karras, CEO of Halo. “Further, Isaac is a preeminent scientist in this field and having his guidance will be a tremendous asset for our customers who may face challenges with bioavailability or even want to pursue abuse deterrent technologies which HME can potentially provide”, Mr. Karras went on to say.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019